Express Scripts (ESRX) Tops Q1 EPS by 1c; Guides Above
More News related to ESRX
- Stifel Nicolaus Initiates Coverage on Express Scripts (ESRX) with a Hold
- UBS Starts Numerous Healthcare Stocks: CAH, MCK, ESRX at Buy, PMC, OCR at Neutral
- InvestorSoup.com issues Technical Trading Outlook for Health Sciences Group Inc.
- Griffin's Blue Ridge Likes A Major Bank, Swaps Into Gold Miner ETF, Picks Up More Silver and Makes Moves In Tech
- Express Scripts to Build High Volume Filler Pharmacy in St. Louis
More News related to Earnings
- Brean Murray Maintains a 'Buy' on Tech Data (TECD); Raises PT to $50
- Analyst Suggests Buying Intuitive Surgical 'Aggressively on Any Pullbacks' (ISRG)
- Citi Maintains a 'Buy' Rating on Ciena Corp (CIEN); Raises PT
- Citi Maintains a 'Buy' Rating on Analog Devices (ADI); Raises Price Target
- Morgan Stanley Lifts Target on Campell Soup (CPB) to $35; Maintains Equal Weight
Express Scripts, Inc. (NASDAQ: ESRX) reports Q3 EPS of $0.81, 1 cents better than the analyst estimate of $0.80. Revenue for the quarter was $5.62 billion, which compares to the estimate of $5.54 billion.
EPS of $3.76-$3.82, versus the consensus of $3.49
Related Categories
EarningsGuidance
Stocks Mentioned
+0.29Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
